GLP-1 for Sleep Apnea: Tirzepatide, Semaglutide, and OSA Research
Sleep apnea and weight are deeply connected
If you have been told to lose weight to improve your sleep apnea, you understand the frustration. The advice is not wrong, but it often comes across as simple when the reality is not. Weight and sleep apnea are connected through biology, not character. And new evidence shows that GLP-1 medications may be a medical tool that actually addresses this connection in a meaningful way.
Sleep apnea is a condition where your airway collapses or narrows repeatedly during sleep, blocking airflow and waking you up. The more excess tissue in your throat and neck, the more likely this is to happen. Obesity is the single most modifiable risk factor for obstructive sleep apnea. That means weight loss is the most effective lifestyle intervention for improving or resolving OSA.
This is why researchers began testing whether GLP-1 medications, which support significant weight loss, could help improve sleep apnea severity. The answer is yes.
The connection between obesity and sleep apnea
Obstructive sleep apnea happens when soft tissue in your throat collapses during sleep, blocking your airway. Your body momentarily wakes you up so you can breathe again. This can happen dozens or even hundreds of times per night.
Obesity dramatically increases OSA risk because excess adipose tissue deposits around your neck and throat compress the airway, making it more likely to collapse. Research from the American Academy of Sleep Medicine and the National Heart, Lung, and Blood Institute shows that approximately 40-70% of adults with OSA have obesity. Conversely, about 40-45% of people with obesity have sleep apnea.
Weight loss is the most effective non-surgical treatment for OSA. Even moderate weight loss of 10-15% can meaningfully reduce sleep apnea severity for many patients. For some, significant weight loss leads to OSA resolution or reduction from severe to mild.
The challenge has always been that weight loss is difficult for many people, especially those with obesity-related metabolic dysfunction. This is where GLP-1 medications enter the picture.
The SURMOUNT-OSA trial: What changed
In December 2024, the FDA approved tirzepatide (prescribed for weight management) as the first weight loss medication specifically indicated for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity[1]. This approval was based on the SURMOUNT-OSA trial, published in the New England Journal of Medicine in 2024.
Here is what the trial showed.
Researchers conducted two parallel studies with a combined enrollment of approximately 469 participants. One trial included patients not using CPAP therapy. The other included patients already using CPAP. Both groups received either tirzepatide or placebo for 52 weeks.
The primary outcome was change in the apnea-hypopnea index (AHI), which measures sleep apnea severity. A lower AHI means less frequent breathing interruptions.
In the non-CPAP group, tirzepatide reduced AHI by approximately 27 events per hour compared to placebo, which reduced AHI by approximately 4 events per hour[2]. This represents a clinically significant improvement in sleep apnea severity.
In the CPAP group, similar patterns emerged. Patients taking tirzepatide while continuing CPAP saw additional improvement in AHI beyond what CPAP alone achieved.
Weight loss in the tirzepatide group averaged 20-22% of baseline body weight over 52 weeks. The improvement in sleep apnea tracked closely with the amount of weight lost.
This is the first large, randomized controlled trial demonstrating that a GLP-1 medication directly improves sleep apnea in patients with obesity. It is also the reason the FDA granted this specific indication to tirzepatide.
How weight loss improves sleep apnea
The mechanism is straightforward. Reducing body weight, particularly upper body fat, decreases the amount of soft tissue compressing your airway during sleep. This makes airway collapse less likely.
When you lose weight on a GLP-1 medication, you are not just losing scale pounds. You are reducing the adipose tissue deposits in your neck and throat that narrow your airway. This directly reduces AHI and can improve oxygen levels during sleep.
This is why the benefit is significant for patients whose sleep apnea is driven primarily by obesity. However, it is also why weight loss does not guarantee complete resolution of OSA. Other anatomical factors (jaw position, tonsil size, nasal passages) also contribute. For some patients, significant weight loss results in OSA resolution. For others, it results in improvement but not cure.
Your sleep specialist will monitor your AHI and oxygen levels as you lose weight to determine how much improvement you achieve.
Tirzepatide vs. semaglutide for sleep apnea
Tirzepatide has direct clinical trial evidence for sleep apnea improvement through the SURMOUNT-OSA trial and the FDA approval that followed. This is specific, branded evidence.
Semaglutide does not have equivalent large, controlled trials demonstrating OSA improvement. However, semaglutide also supports weight loss and would theoretically benefit OSA through the same mechanism. Some observational data and patient reports suggest sleep quality improvement with GLP-1 medications generally. But the controlled trial evidence is stronger for tirzepatide in the OSA population specifically.
If sleep apnea is a key concern for you, tirzepatide has stronger evidence. If you have other health considerations alongside OSA, your provider may recommend semaglutide or another option. The decision is individualized based on your complete health history.
Important note: The SURMOUNT-OSA trial and FDA approval apply to brand-name, FDA-approved tirzepatide prescribed for weight management. Compounded tirzepatide contains the same active ingredient but is not FDA-approved and has not been evaluated in OSA trials.
Sleep apnea as a qualifying condition for GLP-1 treatment
Obstructive sleep apnea is a recognized weight-related condition that qualifies you for GLP-1 treatment under the broader eligibility criteria. Specifically, if you have OSA and a BMI of 27 or higher, you meet the threshold for medical weight management (BMI 27-30 with a weight-related condition qualifies for treatment).
Your provider will evaluate your complete health history, including your OSA diagnosis, current CPAP use, oxygen levels during sleep, and your weight. The provider makes the clinical judgment: Is GLP-1 treatment appropriate and safe for you?
Not everyone with sleep apnea will be a candidate. Your provider will consider your overall health, any other conditions you have, and medications you are taking.
Managing CPAP and GLP-1 treatment together
If you are currently using CPAP therapy, you can continue using it while starting GLP-1 medication. In fact, the SURMOUNT-OSA trial included CPAP users, showing that the two approaches can work together.
As you lose weight on GLP-1 medication and your AHI improves, your sleep specialist may recommend adjusting your CPAP settings or reducing the pressure level. Some patients find they need CPAP less frequently as their apnea severity decreases. Some eventually discontinue CPAP entirely if their OSA resolves.
However, these are decisions your sleep specialist makes based on your specific sleep study results and oxygen levels. Do not adjust or discontinue CPAP on your own. The medication and CPAP work best when coordinated through your providers.
What Transformation Health evaluates for sleep apnea
When you complete an assessment with Transformation Health, your information goes to an independent, licensed provider. That provider reviews your health history, including your OSA diagnosis, your current CPAP use, your oxygen levels if available, and your goals.
The provider makes a clinical judgment: Is GLP-1 treatment appropriate for your specific situation? This is a medical decision, not an automatic approval. If the provider determines that treatment is appropriate, your medication is prepared by a licensed US compounding pharmacy. Your monthly fee includes the medication, your provider’s ongoing care, any required lab work, and access to our medical weight loss coaching.
Residents of Arkansas, Delaware, Mississippi, New Mexico, Rhode Island, Washington DC, and West Virginia are required by state law to complete a live video consultation before a prescription can be written.
What to know about our medications
Transformation Health works exclusively with US-based, licensed compounding pharmacies. Our semaglutide and tirzepatide are compounded medications, not FDA-approved branded products.
The active ingredient (semaglutide or tirzepatide) has been studied in clinical trials and is FDA-approved when made by the brand manufacturers. Our compounded versions contain the same active ingredient but are prepared by a licensed compounding pharmacy. Compounded medications are not FDA-approved products. They have not been independently evaluated by the FDA for safety, efficacy, or quality, and they may differ from branded versions in formulation, purity, or potency.
Our pricing is all-inclusive. Your monthly fee covers medication, lab work (through Quest or Labcorp), provider consultations, and access to our coaching team. No hidden fees. You can cancel anytime.
Semaglutide starts at $249 per month for the injectable version or $279 for the oral version. Tirzepatide is $339 per month. These prices include everything. Your provider will recommend which medication, dose, and delivery method is appropriate for you.
How to get started
Get a GLP-1 Prescription Complete a free online assessment. Tell us about your sleep apnea diagnosis, your CPAP use (if any), your weight history, and your goals. An independent, licensed provider reviews your information and responds within 24 hours to let you know if treatment is appropriate for you. If it is, your medication ships within days.
You can also review our GLP-1 Eligibility Guide if you want to understand the full qualification criteria before starting an assessment.
For a detailed comparison of semaglutide and tirzepatide, including which medication tends to work better for specific situations, see Semaglutide vs Tirzepatide.
Important: Compounded medications are not FDA-approved products and have not been evaluated in OSA clinical trials. The OSA benefit evidence cited on this page is from trials of the brand-name formulation of tirzepatide for chronic weight management. Compounded tirzepatide uses the same active ingredient but is not the same product, and Transformation Health is not affiliated with the manufacturer of that branded product. All prescriptions require evaluation by an independent, licensed healthcare provider. Not all patients will qualify. Results vary by individual.
Citations
[1] FDA. “FDA Approves First Medication for Sleep Apnea.” Press announcement, December 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
[2] Malhotra A et al. “Tirzepatide for Obstructive Sleep Apnea.” New England Journal of Medicine. 2024;390(16):1466-1475. https://pubmed.ncbi.nlm.nih.gov/38912654/